Aung Naing

79PUBLICATIONS
259CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (79)

|Oct 01, 2026
The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.

|Sep 18, 2026
CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer.

|Jun 24, 2026
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

|Jun 08, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

|May 08, 2026
Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies.

|Apr 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.

Pageof 14

Frequent Collaborators

15 joint publications

Vivek Subbiah

15 joint publications

Funda Meric-Bernstam

14 joint publications

Apostolia-Maria Tsimberidou

13 joint publications

Siqing Fu